On 10 October 2019, Sudan notified the World Health Organization (WHO) of 47 suspected cases of Rift Valley Fever, including two deaths in Arb’aat Area, Towashan Village, in El Qaneb locality, Red Sea State.
Researchers assigned 440 participants to receive two doses of MVA followed by one dose of the established replicating-vaccinia vaccine ACAM2000 (the MVA group) or to receive one dose of ACAM2000 (the ACAM2000-only group). No safety concerns associated with the MVA vaccine were identified, and immune responses and attenuation of the major cutaneous reaction suggest the MVA vaccine protected against variola infection.
Tychan‘s monoclonal antibody candidate treatment for Yellow Fever has successfully completed Phase 1A/1B safety trials in Singapore.
The US Defense Threat Reduction Agency (DTRA) has awarded $35.7 million dollars to develop a recombinant vesicular stomatitis virus vector Marburg virus vaccine.
Outdoor farms are emerging in Europe due to an increase in organic farming. Depending on the country and local practices, pig production may have the highest biosecurity levels, to no biosecurity.
Experts from nine Central African nations met to advance biosafety and biosecurity in the region. Participants agreed to set biosecurity and biosafety capacity building goals for the region and track progress.
The World Health Organization (WHO) has little recourse if countries do not meet their obligations to protect global health. A bioweapons treaty might provide a fix.
Officials said the patients came from a remote part of Inner Mongolia in Northern China.
The European Commission announced it has granted a marketing authorization of Merck's Ebola vaccine Ervebo.
An experimental dengue vaccine has shown promising results in a large trial, but critical questions remain about effectiveness and safety. It is unknown whether the vaccine might increase disease severity in some recipients.